Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Confirms Rumors With $3.9bn Deal For AAA's Nuclear Med Biz

Executive Summary

Recent speculation about Novartis' interest in nuclear medicine specialist AAA has been confirmed, after the pharma giant inked a deal worth $3.9bn to acquire the French firm. Integrating AAA would add to Novartis' expertise in diseases associated with neuroendocrine tumors and bring it a new technology platform for treating cancer.

You may also be interested in...



M&A Analysis: October Notches 30 Deals In Big M&A Boom

The medtech M&A deal count soared in October with a total of 30 deals announced and closed in the month. It was an especially busy month for the orthopedics sector, with a number of high profile deals inked.

Keeping Track: Review Underway For Linhaliq, New Uses Of Lenvima, Cimzia; New Cycle Starts For Lutathera

The latest drug development news and highlights from our US FDA Performance Tracker.

Advanced Accelerator Preps Lutetium-Tipped Warhead For NETs Filing

Topics

Related Companies

UsernamePublicRestriction

Register

MT121696

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel